Lataa...
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However,...
Tallennettuna:
| Julkaisussa: | J Hepatocell Carcinoma |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918267/ https://ncbi.nlm.nih.gov/pubmed/27508178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S45040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|